ContraFect's EPS (Basic) for the
three
months ended in Sep. 2023 was $-0.50.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-19.27.
ContraFect's EPS without NRI for the
three
months ended in Sep. 2023 was $-0.61.
Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-25.95.
During the past 3 years, the average EPS without NRIGrowth Rate was 23.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 25.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 30.10% per year.
During the past 11 years, ContraFect's highest 3-Year average EPS without NRI Growth Rate was 49.30% per year. The lowest was 19.10% per year. And the median was 31.35% per year.
ContraFect Earnings per Share (Diluted) Historical Data
The historical data trend for ContraFect's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ContraFect's Earnings per Share (Diluted)
For the Biotechnology subindustry, ContraFect's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContraFect's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ContraFect's PE Ratio distribution charts can be found below:
* The bar in red indicates where ContraFect's PE Ratio falls into.
ContraFect Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ContraFect's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
ContraFect (OTCPK:CFRXQ) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ContraFect Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of ContraFect's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CFRXQ has been successfully added to your 